In a 69-year-old woman with a single episode of microscopic hematuria (seven red blood cells per high-power field), negative urine cytology, and negative CT urography, what is the appropriate next diagnostic step and management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Cystoscopy Should Be Performed Next

This 69-year-old woman requires white light cystoscopy to complete her hematuria evaluation, as she is classified as high-risk based on age alone and has already completed upper tract imaging. 1

Risk Stratification

According to the 2020 AUA/SUFU guidelines, this patient falls into the high-risk category based on:

  • Age ≥60 years (she is 69)
  • 7 RBCs/HPF falls within the 3-10 range (low degree of hematuria, but age supersedes this)

The AUA risk stratification system clearly states that women or men age ≥60 years automatically qualify as high-risk, regardless of other factors 1.

Completed Workup Elements

She has already undergone:

  • Negative CT urography (CTU) - appropriate upper tract imaging
  • Negative urine cytology
  • Negative FISH test

Missing Critical Component: Cystoscopy

White light cystoscopy is mandatory for bladder evaluation in all patients undergoing microscopic hematuria workup 1. The guideline provides a moderate recommendation (Evidence Level Grade C) that clinicians should perform white light cystoscopy in patients undergoing evaluation of the bladder for microhematuria.

Why Cystoscopy Cannot Be Skipped

  • Bladder cancer is the most common malignancy detected in hematuria evaluations 2
  • Upper tract imaging (CTU) does not adequately visualize the bladder mucosa, urethra, or ureteral orifices 3
  • Even with negative cytology, cystoscopy remains essential as cytology has poor sensitivity for low-grade tumors 3
  • This is a single episode of hematuria, but in a high-risk patient (age 69), evaluation is still warranted

Post-Cystoscopy Management

If Cystoscopy is Negative:

Given this is a single episode of microscopic hematuria with completely negative workup:

Surveillance approach 1:

  • Repeat urinalysis at 12 months
  • If repeat UA shows persistent or recurrent microhematuria: engage in shared decision-making regarding additional evaluation
  • If repeat UA is negative: patient can be discharged from further hematuria-specific monitoring

Triggers for immediate re-evaluation 1:

  1. Gross hematuria develops
  2. Abnormal urinary cytology on follow-up
  3. Irritative voiding symptoms without infection
  4. Significant increase in degree of microhematuria

If Cystoscopy is Positive:

  • Refer to urology for definitive management based on findings

Common Pitfall to Avoid

Do not assume the workup is complete without cystoscopy simply because imaging and cytology are negative. The 2020 AUA guidelines emphasize that cystoscopy and upper tract imaging are complementary, not interchangeable 1. Bladder lesions, particularly flat lesions like carcinoma in situ, can be missed without direct visualization.

Special Consideration for Single Episode

While the guidelines acknowledge that a single episode of microhematuria in truly low-risk patients might not require full evaluation, age ≥60 years overrides this consideration 1. The risk of delayed bladder cancer diagnosis in this age group outweighs the risks and costs of cystoscopy, which can be performed safely in the office setting with flexible cystoscopy under local anesthesia 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.